A Novel Combinatorial Regimen Using Sorafenib and Uttroside B, A US FDA-designated ‘Orphan Drug’, for the Treatment of Hepatocellular Carcinoma
Our results highlight the potential of Utt-B as an effective chemosensitizer, which can augment the efficacy of Sor against HCC and circumvent Sor-induced toxic side effects. Moreover, this is the first and only report to date on the chemosensitizing potential of Utt-B and the only report that demonstrates the therapeutic efficacy and pharmacological safety of a novel combinatorial regimen involving Utt-B and Sor for combating HCC.
Authors
- Chenicheri K. Keerthana
- Sankar Sundaram
- Kuzhuvelil B. Harikumar (ORCID: https://orcid.org/0000-0002-1763-4179)
- Shirley James
- Ravi S. Lankalapalli (ORCID: https://orcid.org/0000-0001-8223-7674)
- Ruby John Anto (ORCID: https://orcid.org/0000-0001-5856-0076)
- Tennyson P. Rayginia
- Sadiq C. Shifana
- Yadu Vijayan (ORCID: https://orcid.org/0009-0009-2036-0699)
- D. K. Induja
- Sreekumar U. Aiswarya
Institutions
- National Institute for Interdisciplinary Science and Technology (IN)
- University of Kerala (IN)
- Government Medical College (IN)
- Rajiv Gandhi Centre for Biotechnology (IN)
Publication Details
- Journal
- Anti-Cancer Agents in Medicinal Chemistry
- Published
- 2024-08-12
- DOI
- https://doi.org/10.2174/0118715206316190240527160242
- Citations
- 3
- Primary Topic
- Phytochemical Studies and Bioactivities
- Type
- article
- Field-Weighted Citation Impact
- 0.70